Matthew Ros
2018
In 2018, Matthew Ros earned a total compensation of $1.7M as Chief Strategy and Business Officer at Epizyme, a 18% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $187,100 |
|---|---|
| Option Awards | $1,099,576 |
| Salary | $420,000 |
| Other | $12,214 |
| Total | $1,718,890 |
Ros received $1.1M in option awards, accounting for 64% of the total pay in 2018.
Ros also received $187.1K in non-equity incentive plan, $420K in salary and $12.2K in other compensation.
Rankings
In 2018, Matthew Ros' compensation ranked 6,490th out of 14,244 executives tracked by ExecPay. In other words, Ros earned more than 54.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,490 out of 14,244 | 54th |
Division Manufacturing | 2,480 out of 5,759 | 57th |
Major group Chemicals And Allied Products | 922 out of 2,122 | 57th |
Industry group Drugs | 774 out of 1,811 | 57th |
Industry Pharmaceutical Preparations | 602 out of 1,385 | 57th |
Source: SEC filing on April 18, 2019.
Ros' colleagues
We found four more compensation records of executives who worked with Matthew Ros at Epizyme in 2018.